The French firm unveiled data from its pancreatic cancer trial showing Onivyde plus chemotherapy improved median PFS by just over a month compared with current treatment of choice but failed to beat its overall survival benchmark.

MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.

The French firm’s Onivyde has succeeded as part of a combination regimen in chemotherapy-naïve pancreatic cancer patients, setting it up for a label expansion, but some experts are keen to see survival data in full before raising guidance.

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.